首页 | 本学科首页   官方微博 | 高级检索  
     


Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis
Authors:Ahmad Hassan Ali  Jennifer Damman  Shamita B. Shah  Yinka Davies  Melissa Hurwitz  Mariam Stephen
Affiliation:1. Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA;2. Division of Hepatology, University of Missouri-Columbia, Columbia, MO, USA;3. Texas Tech University Health Sciences Center, Amarillo, TX, USA;4. Lucile Packard Children’s Hospital, Stanford University, Palo Alto, CA, USA;5. Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA;6. Division of Gastroenterology, Ochsner Clinic Foundation, New Orleans, LA, USA;7. Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, CA, USA;8. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA;9. Lucile Packard Children’s Hospital, Stanford University, Stanford, CA, USA
Abstract:Abstract

Background

Oral vancomycin (OV) in primary sclerosing cholangitis (PSC) has been evaluated as a potential therapeutic agent. We report the long-term biochemical course and outcomes of patients with PSC treated with OV.
Keywords:Primary sclerosing cholangitis  cirrhosis  liver biochemistry  cholangiography  inflammatory bowel disease  and ulcerative colitis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号